03 March 2015 : Clinical Research
Concurrent Chemoradiotherapy with Vinorelbine plus Split-Dose Cisplatin may be an Option in Inoperable Stage III Non-Small Cell Lung Cancer: A Single-Center Experience
Hüseyin MertsoyluABCDEFG, Fatih KöseABCDEFG, Ahmet Taner SümbülABCDEFG, Ali Murat SedefABCDEFG, Özlem DoğanABCDE, Ali Ayberk BesenABCD, Cem ParlakABCD, Alper FındıkçıoğluABC, Sadık MuallaoğluABCD, Ahmet SezerABCD, Hakan SakallıABCD, Özgür ÖzyılkanABCDEFDOI: 10.12659/MSM.892730
Med Sci Monit 2015; 21:661-666
Abstract
BACKGROUND: Concurrent chemoradiotherapy is the current standard treatment for inoperable stage III non-small cell lung cancer (NSCLC). In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) in patients with inoperable stage III NSCLC followed in our oncology clinic.
MATERIAL AND METHODS: Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with cisplatin-vinorelbine were retrospectively analyzed. Cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) were administered on days 1, 8, 22, and 29 during radiotherapy. Two cycles of consolidation chemotherapy were given. All patient data, including pathological, clinical, radiological, biochemical, and hematological data, were assessed retrospectively using our database system.
RESULTS: Our study included 97 unresectable stage III NSCLC patients who were treated with CCRT. Median age was 58 years old (range 39–75) and 87 (89.7%) of the patients were men. ECOG performance score was 0–1 in 93 patients (95.9%). Squamous histology, the most common histology, was diagnosed in 46 patients (47.4%). Median follow-up time was 23.8 months. Median progression-free survival (PFS) and median overall survival time (OS) were 10.3 months and 17.8 months, respectively. Objective response rate and clinical benefit rate were 75.3% and 83.5%, respectively. Distant and local relapse rate were 57.1% and 42.9%, respectively. Hematological and non-hematological grade 3–4 toxicities were seen in 13 (13.4%) and 16 (16.5%) patients, respectively. Six (6.1%) patients died due to toxicity.
CONCLUSIONS: The results of this study suggest that split-dose cisplatin may offer fewer grade III–IV toxicities without sacrificing efficacy and could be an option in patients with inoperable stage III NSCLC during CCRT. Similar to past studies, despite high response rate during CCRT, distant relapse is the major parameter that influences patient survival in long-term in NSCLC.
Keywords: Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Carcinoma, Non-Small-Cell Lung - therapy, Chemoradiotherapy - adverse effects, Cisplatin - therapeutic use, Consolidation Chemotherapy, Disease-Free Survival, Dose-Response Relationship, Drug, Kaplan-Meier Estimate, Lung Neoplasms - therapy, Neoplasm Staging, Vinblastine - therapeutic use
Editorial
01 May 2022 : Editorial
Editorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19DOI: 10.12659/MSM.937048
Med Sci Monit 2022; 28:e937048
SARS-CoV-2/COVID-19
16 May 2022 : Clinical Research
Importance of Influenza Anti-Hemagglutinin Antibodies During the SARS-CoV-2 Pandemic in the 2019/2020 Epide...Med Sci Monit In Press; DOI: 10.12659/MSM.936495
04 May 2022 : Clinical Research
Effects of Wearing Face Masks on Exercise Capacity and Ventilatory Anaerobic Threshold in Healthy Subjects ...Med Sci Monit In Press; DOI: 10.12659/MSM.936069
22 April 2022 : Clinical Research
Factors Associated with Falls During Hospitalization for Coronavirus Disease 2019 (COVID-19)Med Sci Monit In Press; DOI: 10.12659/MSM.936547
27 April 2022 : Meta-Analysis
Effect of the COVID-19 Pandemic on Serum Vitamin D Levels in People Under Age 18 Years: A Systematic Review...Med Sci Monit In Press; DOI: 10.12659/MSM.935823
In Press
18 May 2022 : Clinical Research
Physical and Psychosocial Concept Domains Related to Health-Related Quality of Life (HRQL) in 50 Girls and ...Med Sci Monit In Press; DOI: 10.12659/MSM.936801
18 May 2022 : Clinical Research
Association Between Variants of the Mannose-Binding Lectin 2 Gene and Susceptibility to Sepsis in the Haina...Med Sci Monit In Press; DOI: 10.12659/MSM.936134
17 May 2022 : Clinical Research
Clinical Application of C-TIRADS Category and Contrast-Enhanced Ultrasound in Differential Diagnosis of Sol...Med Sci Monit In Press; DOI: 10.12659/MSM.936368
17 May 2022 : Laboratory Research
Artificial Dermal Scaffold Loaded with Platelet-Rich Plasma Promotes Wound Healing in Pigs by Favoring Angi...Med Sci Monit In Press; DOI: 10.12659/MSM.936186
Most Viewed Current Articles
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review article
Long-Term Respiratory and Neurological Sequelae of COVID-19DOI :10.12659/MSM.928996
Med Sci Monit 2020; 26:e928996
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952